Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Reports Positive Results for CAR T Therapy in Solid Tumor Cancers

publication date: May 13, 2022

CARsgen, a Shanghai CAR T-cell company, reported positive results in the journal Nature Medicine for its Claudin18.2 CAR T in patients with solid tumor cancers. Interim results from an investigator-led Phase I trial showed the CT041 was effective in patients with advanced gastrointestinal cancers and gastroesophageal junction adenocarcinoma. In 37 patients, the objective response rate was 48.6% with a disease control rate of 73%. CARsgen said that, currently, CT041 is the world's first and only CAR T-cell candidate to start a confirmatory Phase II clinical trial in solid tumor cancers. More details....

Stock Symbol: (HK: 2171)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital